{
    "clinical_study": {
        "@rank": "131236", 
        "arm_group": [
            {
                "arm_group_label": "Monotherapy Cohort", 
                "arm_group_type": "Experimental", 
                "description": "PF-04449913 Monotherapy"
            }, 
            {
                "arm_group_label": "Combination Cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "PF-04449913 in combination with low dose ARA-C (LDAC)"
            }, 
            {
                "arm_group_label": "Combination Cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "PF-04449913 in combination with intensive chemotherapy: PF-04449913 administered continuously for 28 days. Daunorubicin given using 60 mg/m2 for 3-days together with cytarabine 100 mg/m2 on days 1 through 7 followed by cytarabine 1g/m2 on days 1, 3, and 5 during 2-4 cycles of consolidation therapy."
            }
        ], 
        "brief_summary": {
            "textblock": "This is an open-label, multi-center, Phase 1 study of PF-04449913 in Japanese patients.\n      PF-04449913 will be administered orally as a single agent in patients with select advanced\n      hematologic malignancies, or in combination with LDAC [Low-Dose Ara-C] or cytarabine and\n      daunorubicin in previously untreated patients with AML [Acute Myeloid Leukemia] or high-risk\n      MDS [Myelodysplastic Syndrome]."
        }, 
        "brief_title": "A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Myeloid Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid", 
                "Myelodysplastic Syndromes", 
                "Hematologic Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with select advanced hematologic malignancies who are refractory, resistant\n             or intolerant to prior therapies for monotherapy cohort.\n\n          -  Patients with AML or High-Risk MDS who are newly diagnosed and previously untreated\n             for combination cohort.\n\n          -  ECOG [Eastern Cooperative Oncology Group] performance status 0 to 2\n\n          -  Adequate organ function\n\n        Exclusion Criteria:\n\n          -  Patients with active CNS disease\n\n          -  Patient with active malignancy with the exception of basal cell carcinoma, non\n             melanoma skin cancer, carcinoma in situ cervical\n\n          -  Patient has an active, life threatening or clinically significant uncontrolled\n             systemic infection"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02038777", 
            "org_study_id": "B1371005"
        }, 
        "intervention": [
            {
                "arm_group_label": "Monotherapy Cohort", 
                "description": "PF-04449913 administered orally and continuously in 28 day cycles.", 
                "intervention_name": "PF-04449913", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Combination Cohort 1", 
                "description": "PF-04449913 administered orally and continuously in 28 day cycles.", 
                "intervention_name": "PF-04449913", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Combination Cohort 1", 
                "description": "Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.", 
                "intervention_name": "Low dose ARA-C (LDAC)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Combination Cohort 2", 
                "description": "PF-04449913 administered orally and continuously in 28 day cycles.", 
                "intervention_name": "PF-04449913", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Combination Cohort 2", 
                "description": "Daunorubicin given using 60 mg/m2 for 3-days.", 
                "intervention_name": "Daunorubicin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Combination Cohort 2", 
                "description": "Cytarabine 100 mg/m2 on days 1 through 7.", 
                "intervention_name": "Cytarabine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cytarabine", 
                "Daunorubicin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Hematologic Malignancies", 
        "lastchanged_date": "May 28, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1371005&StudyName=A%20Study%20Of%20PF-04449913%20In%20Japanese%20Patients%20With%20Select%20Hematologic%20Malignancies"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Kobe-shi", 
                        "country": "Japan", 
                        "state": "Hyogo"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sendai", 
                        "country": "Japan", 
                        "state": "Miyagi"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fukuoka", 
                        "country": "Japan"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 1 Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04449913, An Oral Hedgehog Inhibitor, Administered As A Single Agent In Japanese Patients With Select Hematologic Malignancies And In Combination With Intensive Chemotherapy Or Low-Dose Ara-C In Patients With Acute Myeloid Leukemia Or High-Risk Myelodysplastic Syndrome", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "First cycle Dose Limiting Toxicities", 
            "safety_issue": "Yes", 
            "time_frame": "28 days after first dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02038777"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Maximum observed plasma concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Time to reach maximum observed plasma concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Area under the plasma concentration curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Objective disease response", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Disease-related gene mutation (PD biomarkers)", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Detectable tumor Gli1 expression (PD Biomarkers)", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}